Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Income from Continuing Operations readings, the most recent being 10042000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 30.3% to 10042000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 35482000.0 through Mar 2026, down 31.23% year-over-year, with the annual reading at 33147000.0 for FY2025, 35.39% down from the prior year.
  • Income from Continuing Operations hit 10042000.0 in Q1 2026 for DiaMedica Therapeutics, down from 9121000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3059000.0 in Q3 2022 and bottomed at 10042000.0 in Q1 2026.
  • Average Income from Continuing Operations over 5 years is 5925176.47, with a median of 5161000.0 recorded in 2023.
  • The largest annual shift saw Income from Continuing Operations rose 11.33% in 2022 before it plummeted 53.81% in 2024.
  • DiaMedica Therapeutics' Income from Continuing Operations stood at 3751000.0 in 2022, then tumbled by 37.59% to 5161000.0 in 2023, then plummeted by 53.81% to 7938000.0 in 2024, then decreased by 14.9% to 9121000.0 in 2025, then decreased by 10.1% to 10042000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Income from Continuing Operations are 10042000.0 (Q1 2026), 9121000.0 (Q4 2025), and 8620000.0 (Q3 2025).